Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III …
B Shakoory, JA Carcillo, WW Chatham… - Critical care …, 2016 - journals.lww.com
Objective: To determine the efficacy of anakinra (recombinant interleukin-1 receptor
antagonist) in improving 28-day survival in sepsis patients with features of macrophage
activation syndrome. Despite equivocal results in sepsis trials, anakinra is effective in
treating macrophage activation syndrome, a similar entity with fever, disseminated
intravascular coagulation, hepatobiliary dysfunction, cytopenias, and hyperferritinemia.
Hence, sepsis patients with macrophage activation syndrome features may benefit from …
antagonist) in improving 28-day survival in sepsis patients with features of macrophage
activation syndrome. Despite equivocal results in sepsis trials, anakinra is effective in
treating macrophage activation syndrome, a similar entity with fever, disseminated
intravascular coagulation, hepatobiliary dysfunction, cytopenias, and hyperferritinemia.
Hence, sepsis patients with macrophage activation syndrome features may benefit from …